Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nevada Norris

Physician Assistant Aventura, FL Physician Assistant

NPI 1295327914 CMS profile 11255699

18801 Ne 29Th Ave, Aventura, FL 33180

Open in the dashboard

General payments

$20,523

568 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nevada Norris of Aventura, FL is reported in the CMS Open Payments database as having received $20,523 across 568 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,384 156
2024 General $4,324 139
2023 General $2,900 114
2022 General $5,893 158
2021 General $22 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nevada Norris
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nevada Norris were reported at $7,384. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nevada Norris Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $22 $132 $37–$438 $132
2022 $5,893 $155 $48–$522 $149
2023 $2,900 $167 $52–$557 $160
2024 $4,324 $178 $55–$600 $164
2025 $7,384 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Galderma Laboratories, L.P. $4,329 33 payments
  2. AbbVie, Inc. $3,467 123 payments
  3. Janssen Biotech, Inc. $1,842 62 payments
  4. Amgen Inc. $1,547 19 payments
  5. Incyte Corporation $1,177 34 payments
  6. Genzyme Corporation $981 27 payments
  7. Pfizer Inc. $893 31 payments
  8. Regeneron Healthcare Solutions, Inc. $859 23 payments
  9. Janssen Scientific Affairs, LLC $808 8 payments
  10. UCB, Inc. $763 27 payments
  11. Other $3,855 181 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,046 563 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,300 2 payments
  3. Education $177 3 payments
Products named General payments · program years 2021–2025
  1. AKLIEF $3,322 3 payments
  2. TREMFYA $2,555 65 payments
  3. RINVOQ $1,409 52 payments
  4. DUPIXENT $1,271 35 payments
  5. SKYRIZI $1,197 39 payments
  6. OPZELURA $1,177 34 payments
  7. Otezla $925 14 payments
  8. CIBINQO $723 27 payments
  9. SOTYKTU $702 21 payments
  10. NEMLUVIO $545 9 payments
  11. Other $6,598 316 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,288

Median for Physician Assistant: 241

Drug cost

$339,744

Median for Physician Assistant: $4,110

Branded share of claims

3.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 37 $155,551
Cosentyx Sensoready (2 Pens) Secukinumab Brand 15 $120,592
Clobetasol Propionate Generic 367 $12,481
Ketoconazole Generic 445 $6,576
Ciclopirox Generic 144 $6,210
Ammonium Lactate Generic 188 $4,599
Triamcinolone Acetonide Generic 306 $4,591
Metronidazole Generic 70 $4,412
Fluorouracil Generic 45 $4,087
Pimecrolimus Generic 12 $3,589

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$496 — —
TREMFYA
$443 — —
Otezla
$375 — —
SOTYKTU
$358 — —
DUPIXENT
$351 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record